Holen Sie sich die Stockscreener-App
261.80
0.33%
0.85
Handel nachbörslich:
261.80
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
KRYS | Krystal Biotech, Inc. Common Executive Compensation - Quiver Quantitative
Krystal Biotech, Inc. ($KRYS) CEO 2025 Pay Revealed - Quiver Quantitative
KRYS PE Ratio & Valuation, Is KRYS Overvalued - Intellectia AI
Krystal Biotech, Inc. (KRYS) Stock forecasts - Yahoo Finance UK
[DEF 14A] Krystal Biotech, Inc. Definitive Proxy Statement - Stock Titan
SG Americas Securities LLC Purchases 15,591 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
3 Insider-Owned Growth Companies With Up To 81% Earnings Expansion - simplywall.st
KRYS Forecast, Price Target & Analyst Ratings | KRYSTAL BIOTECH INC (NASDAQ:KRYS) - ChartMill
KRYS News & Events - intellectia.ai
BSP:K1YS34 PB Ratio: 0.20 — 96% Below Median - GuruFocus
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
(KRYS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Krystal Biotech stock price forecast: consolidation likely as KRYS hovers near key support and down 2.39% - Traders Union
Assessing Krystal Biotech (KRYS) Valuation After Recent Share Price Weakness - finance.yahoo.com
Krystal Biotech (NASDAQ:KRYS) Coverage Initiated at Wolfe Research - Defense World
Krystal Biotech (BSP:K1YS34) Cyclically Adjusted PB Ratio : (As of Apr. 01, 2026) - GuruFocus
Krystal Biotech (BSP:K1YS34) EBITDA per Share : R$30.92 (TTM As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Gross Property, Plant and Equipment : R$1,033 Mil (As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Minority Interest : R$0.00 Mil (As of Dec. 2025) - GuruFocus
Krystal Biotech Inc Phase 1/2 Clinical Trial of KB103 Final Update Call Transcript - GuruFocus
Krystal Biotech Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q3 2024 Krystal Biotech Inc Earnings Call Transcript - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Krystal Biotech (BSP:K1YS34) Shiller PE Ratio : (As of Mar. 28, 2026) - GuruFocus
BSP:K1YS34 Pretax Margin %: 47.74% — 45% Above Median - GuruFocus
Krystal Biotech (BSP:K1YS34) Unearned Premiums - GuruFocus
BSP:K1YS34 Graham Number: R$439.15 — 14786% Above Median - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Dividend - GuruFocus
Krystal Biotech Inc FDA Approval Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Cyclically Adjusted PS Ratio : (As of Mar. 28, 2026) - gurufocus.com
Krystal Biotech (BSP:K1YS34) Other Current Payables : R$-0 Mil (As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Pre-Tax Income : R$1,047 Mil (TTM As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Non Operating Income : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
BSP:K1YS34 Net Income From Continuing Operations: R$1,124 Mi - GuruFocus
Krystal Biotech Inc KB301 Phase 1 POC Efficacy Data Update Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Net Income (Discontinued Opera - GuruFocus
Q4 2024 Krystal Biotech Inc Earnings Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Cyclically Adjusted Price-to-F - GuruFocus
Krystal Biotech Inc Stock Intrinsic Values | BSP:K1YS34 - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Stock Price, Trades & News - gurufocus.com
Q2 2024 Krystal Biotech Inc Earnings Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Gross-Profit-to-Asset % : 31.50% (As of Dec. 2025) - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Krystal Biotech Inc (BSP:K1YS34)Valuation Measures & Financial Statistics - GuruFocus
Krystal Biotech (BSP:K1YS34) Fees and Other Income - GuruFocus
Krystal Biotech (BSP:K1YS34) Degree of Operating Leverage : 1.66 (As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Degree of Financial Leverage : 2.28 (As of Dec. 2025) - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Competitors 2026 - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Valuation - GuruFocus
Krystal Biotech (BSP:K1YS34) ROE % : 17.59% (As of Dec. 2025) - GuruFocus
Krystal Biotech Inc Stock Historical Valuations - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Stock News, Headlines & Updates - GuruFocus
Who's Buying or Selling Krystal Biotech Inc (BSP:K1YS34) Stock Today? - gurufocus.com
Krystal Biotech Inc Stock Baskets - GuruFocus
Krystal Biotech Inc Stock Warning Signs | BSP:K1YS34 - GuruFocus
Krystal Biotech Inc Stock Operating Data - GuruFocus
Moving Averages: Is Krystal Biotech Inc exposed to currency risks2026 Reactions & Smart Money Movement Tracker - baoquankhu1.vn
Vanguard disaggregates holdings after realignment; KRYS shows 0% ownership (KRYS) - stocktitan.net
Wolfe Research Initiates Coverage on Krystal Biotech (NASDAQ:KRYS) - MarketBeat
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Krystal Biotech (KRYS) Valuation Check After Recent Pullback And Mixed Earnings Multiple Signals - Sahm
Total operating expenses of Krystal Biotech Inc Unsponsored BDR – BMFBOVESPA:K1YS34 - TradingView
Krystal Biotech Inc (KRYS) Stock News & Articles - 24/7 Wall St.
Fed Watch: Is Krystal Biotech Inc impacted by rising rates2026 EndofMonth & Verified Swing Trading Watchlist - baoquankhu1.vn
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $325 - Moomoo
Krystal Biotech slips more than 2% even after Q4 earnings and revenue top estimates - msn.com
Published on: 2026-03-23 18:50:19 - baoquankhu1.vn
Why is Krystal Biotech (KRYS) down 11.5% since last earnings report? - msn.com
KRYS SEC FilingsKrystal Biotech 10-K, 10-Q, 8-K Forms - Stock Titan
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch - The Globe and Mail
Krystal Biotech Experiences Revision in Its Stock Evaluation Amid Strong Financial Performance - Markets Mojo
(KRYS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
A Look At Krystal Biotech (KRYS) Valuation After Updated Vyjuvek Label And Pipeline Momentum - simplywall.st
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):